Clinical Trial Update: Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris. [Phase 3]

View source ↗

Summary

Phase 3 study comparing GK530G gel with CD0271 0.1% gel and CD1579 2.5% gel for acne vulgaris; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• CD0271 0.1% Gel (CD0271)
• CD1579 2.5% Gel (CD1579)
• GK530G Gel (GK530G)

Snippet

Sponsor: Galderma R&D | Conditions: Acne Vulgaris | Phase 3 | Status: COMPLETED | Results posted: 2016-11-03